Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468290 | 0.95 | APP (0.44) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL1224639 | 0.93 | AURKA (0.43) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL1192074 | 0.81 | APP (0.52) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL1192095 | 0.79 | CCNE2 (0.47) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL1191456 | 0.79 | APP (0.50) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL22792188 | 0.75 | BRAF (0.53) | CLK4PDGFRBDYRK1AADORA2AADORA2B | |
| SCHEMBL16041322 | 0.73 | APP (0.50) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL27871448 | 0.73 | CLK4 (0.51) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL1225589 | 0.70 | APP (0.47) | APPCLK4CCNE2CCNE1CDK2 | |
| SCHEMBL2902811 | 0.69 | MAPT (0.64) | AURKARPS6KB1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| CN-103339110-A | Substituted hetero-biaryl compounds as CDK9 inhibitors and uses thereof | NOVARTIS AG | 2013-10-02 | — | — | CN | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8415381-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| WO-2012101066-A1 | PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101065-A2 | PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459535-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| CN-102482218-A | Pyridine And Pyrazine Derivatives As Protein Kinase Modulators | NOVARTIS AG | 2012-05-30 | — | — | CN | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | APP 2997/4885CLK4 181/4885CCNE2 97/4885 |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | APP 2997/4885CLK4 181/4885CCNE2 97/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | APP 2997/4885CLK4 181/4885CCNE2 97/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | APP 3543/4885CLK4 177/4885CCNE2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.